Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Bucillamine (Primary)
- Indications Cystinuria
- Focus Adverse reactions; Proof of concept
- Sponsors Revive Therapeutics
- 26 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 26 Feb 2017 Status changed from not yet recruiting to recruiting.
- 21 Dec 2016 According to a Revive Therapeutics media release, company has engaged NYU School of Medicine as one of the Company's clinical sites in this study and this study is expected to be completed by Q2 of 2017.